CES 2021 MedFluid Develops First-In-Class Microfluidic Platform for Rapid Detection and Screening of Disease Diagnosis
Share this article Share this article TAIPEI, Taiwan, Jan. 17, 2021 /PRNewswire/ -- Health and Biotech company MedFluid has developed the fastest, first-in-class antimicrobial susceptibility test that will aid in providing precise medical prescriptions to improve the health and well-being of patients. MedFluid Founder and Head of Microfluidics R&D Bon Lee noted that, according to the World Health Organization (WHO), antimicrobial resistance was one of the ten threats to global health in 2019. "It is happening around the world, and North America alone has more than 2 million cases and 23 thous...
Source: prnewswire.com